Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer – first line
NIHR HSRIC
Record ID 32016000522
English
Authors' recommendations:
Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body.
Nivolumab is a new drug for the treatment of non-small cell lung cancer. It is given as a drip into a vein once every two weeks. Some studies have suggested nivolumab may be used as a first line treatment and helpful for people who have non-small cell lung cancer that has spread to other parts of the body. Studies are currently ongoing to see how well nivolumab works and how safe it is to use.
If nivolumab is licensed for use in the UK, it could be a new treatment option for patients with advanced non-small cell lung cancer, which may improve survival and cause fewer side effects than current treatments (usually chemotherapy).
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/nivolumab-opdivo-for-stage-iv-or-recurrent-non-small-cell-lung-cancer-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- Neoplasm Recurrence, Local
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.